Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ACADEMIA
ACADEMIA
- Cancer Institute Hospital Opens Development Center to Resolve Challenges of Immunotherapy with Pharma Companies
October 18, 2019
- Research Group at Tokyo Medical and Dental Univ. Succeeds in Producing Multi-Organ Structure from iPS Cells
September 27, 2019
- Drug Makers Evaluating MSLs Using Both Qualitative, Quantitative Criteria: JAPhMed Survey
September 25, 2019
- High Response Rate in Brain Metastasis Patients Earned High Marks for Rozlytrek’s Sakigake Status: Oncologist
September 6, 2019
- Anticoagulant Monotherapy Does Not Increase CV Events in Coronary Artery Disease Patients with AF: Cardiovascular Center
September 6, 2019
- 4 Scientific Societies Submit Proposal to Health Minister to Ensure Stable Antibiotic Supplies
September 4, 2019
- Investigator-Led Clinical Trial to Get Underway for Next-Gen Oncolytic Virus
August 28, 2019
- 80% of Diabetes Patients on Antihypertensives Use ACE Inhibitors/ARBs: MHLW Study
August 19, 2019
- 5-Year Cancer Survival Rates in Japan Stand at 66.1%: NCC
August 9, 2019
- NCC Hospital Crafting Scheme to Offer Off-Label Meds after Genomic Profiling
July 23, 2019
- Submission of Oncolytic Virus G47Δ Lagging as Team Still Preps for Manufacturing
July 22, 2019
- After Listing Delayed, Collategene Expected to Reach Market by Year-End: AnGes Founder
July 22, 2019
- Japanese Data More Positive for Keytruda’s Frontline Use in Gastric Cancer
July 22, 2019
- Keytruda Shows Promise in Japanese HCC Patients despite Global Miss
July 22, 2019
- Keytruda Slashes Death Risk by 78% in Japanese Head and Neck Cancer Patients
July 19, 2019
- New Pancreatic Cancer Guidelines Recommend FOLFIRINOX as 1st-Line Therapy
July 19, 2019
- TMDU, Tokyo Govt Join Hands for Open Innovation in Drug Discovery, Healthcare
July 18, 2019
- Virologist Expresses Concern over Spread of Resistant Flu Viruses to Xofluza
July 17, 2019
- Drugs to Replace Nucleic Acid Analogs Being Developed for Hepatitis B, with Focus on Elimination of HBs Antigens
July 12, 2019
- NCC Pitches Creation of New Panel to Address Info Gaps for Cancer Drugs, but Regional Hospitals Wary
July 11, 2019
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…